Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 774

1.

Therapy options in imatinib failures.

Ramirez P, DiPersio JF.

Oncologist. 2008 Apr;13(4):424-34. doi: 10.1634/theoncologist.2007-0170. Review.

2.

Strategies for overcoming imatinib resistance in chronic myeloid leukemia.

Kujawski L, Talpaz M.

Leuk Lymphoma. 2007 Dec;48(12):2310-22. Review.

PMID:
18067005
4.

Overcoming kinase resistance in chronic myeloid leukemia.

Lee F, Fandi A, Voi M.

Int J Biochem Cell Biol. 2008;40(3):334-43. Review.

PMID:
18401881
5.

Important therapeutic targets in chronic myelogenous leukemia.

Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.

Clin Cancer Res. 2007 Feb 15;13(4):1089-97. Review.

6.

Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.

Jabbour E, Cortes J, Kantarjian H.

Expert Opin Investig Drugs. 2007 May;16(5):679-87. Review. Erratum in: Expert Opin Investig Drugs. 2007 Jul;16(7):1135.

PMID:
17461740
7.

Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.

Erba HP, Pham DC, Zaiden R, Vu H, Tai S.

Clin Adv Hematol Oncol. 2011 Oct;9(10):734-45. Review.

PMID:
22252576
8.

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL.

N Engl J Med. 2006 Jun 15;354(24):2531-41.

9.

Targeted chronic myeloid leukemia therapy: Seeking a cure.

Fausel C.

Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15. Review.

PMID:
18056932
10.

Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.

DeAngelo DJ, Attar EC.

Leuk Lymphoma. 2010 Mar;51(3):363-75. doi: 10.3109/10428190903518295. Review.

PMID:
20038231
11.

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.

Kim WS, Kim D, Kim DW, Kweon IY, Kim SH, Goh HG, Park SH, Lee J.

Hematol Oncol. 2010 Jun;28(2):82-8. doi: 10.1002/hon.918.

PMID:
19768693
12.

Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options.

Bauer S, Romvari E.

Clin J Oncol Nurs. 2009 Oct;13(5):523-34. doi: 10.1188/09.CJON.523-534.

PMID:
19793709
13.

Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.

Piccaluga PP, Paolini S, Martinelli G.

Cancer. 2007 Sep 15;110(6):1178-86. Review.

14.

BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.

Wongboonma W, Thongnoppakhun W, Auewarakul CU.

Exp Mol Pathol. 2012 Apr;92(2):259-65. doi: 10.1016/j.yexmp.2012.01.007. Epub 2012 Jan 31.

PMID:
22314255
15.

Targeted drugs in chronic myeloid leukemia.

Gora-Tybor J, Robak T.

Curr Med Chem. 2008;15(29):3036-51. Review.

PMID:
19075651
16.

The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.

Maekawa T, Ashihara E, Kimura S.

Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22. Review.

PMID:
17929114
17.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865 . Review.

PMID:
18491988
18.

Loss of response to imatinib: mechanisms and management.

Shah NP.

Hematology Am Soc Hematol Educ Program. 2005:183-7.

PMID:
16304378
19.

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).

Walz C, Sattler M.

Crit Rev Oncol Hematol. 2006 Feb;57(2):145-64. Epub 2005 Oct 5. Review.

PMID:
16213151
20.

Supplemental Content

Support Center